Trial Profile
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-Based Systemic Therapy and Cranial Radiotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK; Novartis
- 27 Apr 2018 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2018.
- 06 Jun 2017 Planned primary completion date changed from 1 Sep 2007 to 31 Dec 2018.